NCT06617390已完成不适用
Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatment: a Multi-center, Non-interventional and Retrospective Real-world Study (RECAP)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,041
- 试验地点
- 6
- 主要终点
- Percentage of real-world treatment regimens for second- or third-line therapy in patients with advanced NSCLC
研究概览
简要总结
This study will retrospectively collect data of patients with advanced non-small cell lung cancer who have received at least 2 line treatment to investigate treatment patterns, relevant outcomes, and biomarkers detection patterns in Chinese patients with Actionable Genomic Alterations (AGA) or non-AGA.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants aged ≥18 years when diagnosed with advanced NSCLC.
- •Histologically or cytologically confirmed stage IV NSCLC.
- •For non-AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31, 2022, and participants received corresponding immunotherapy in the first or second line.
- •For AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31,
- •Among them, participants with documented positive result for EGFR, ALK, or ROS1 testing received corresponding targeted therapy in the first or second line.
排除标准
- •This study excludes participants who met any of the following criteria.
- •Having records of participation or past participation in clinical trial for lung cancer within the data collection period of the study.
- •Participants with a concomitant cancer at the time of diagnosis of NSCLC (except for non-metastatic non-melanoma skin cancers, in situ or benign neoplasms). Occurrence of cancer within 5 years after NSCLC diagnosis will be considered as secondary cancer.
- •Histology of the tumor is small cell lung cancer, neuroendocrine in origin, or a mixed histologic type with small cell and non-small cell lung cancers.
- •Participants with significantly missing medical record data or patients deemed inappropriate for inclusion by investigators.
结局指标
主要结局
Percentage of real-world treatment regimens for second- or third-line therapy in patients with advanced NSCLC
时间窗: 40 months
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
不适用
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLCNon Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related TumorsNCT04304638Chinese Academy of Medical Sciences450
已完成
不适用
Non-small Cell Lung Cancer and Quality of LifeNon Small Cell Lung CancerNCT00818402University of Turku130
进行中（未招募）
2 期
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung CancerNeoadjuvant TherapyNSCLCNCT05882513Second Affiliated Hospital, School of Medicine, Zhejiang University36
Unknown
不适用
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine KinaseNon-Small-Cell Lung CancerNCT02755337Dr. Soetomo General Hospital70
Unknown
2 期
Curative Study of Chinese Traditional Medicine to Treat Lung CancerCancerNCT02777788Shanghai University of Traditional Chinese Medicine120